158 related articles for article (PubMed ID: 27462136)
1. The Effect of Chronic Alprazolam Intake on Memory, Attention, and Psychomotor Performance in Healthy Human Male Volunteers.
Chowdhury ZS; Morshed MM; Shahriar M; Bhuiyan MA; Islam SM; Bin Sayeed MS
Behav Neurol; 2016; 2016():3730940. PubMed ID: 27462136
[TBL] [Abstract][Full Text] [Related]
2. Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg.
Leufkens TR; Vermeeren A; Smink BE; van Ruitenbeek P; Ramaekers JG
Psychopharmacology (Berl); 2007 May; 191(4):951-9. PubMed ID: 17219217
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers.
Hindmarch I; Trick L; Ridout F
Psychopharmacology (Berl); 2005 Dec; 183(2):133-43. PubMed ID: 16205916
[TBL] [Abstract][Full Text] [Related]
4. Effects of buspirone and alprazolam on the cognitive performance of normal elderly subjects.
Hart RP; Colenda CC; Hamer RM
Am J Psychiatry; 1991 Jan; 148(1):73-7. PubMed ID: 1984710
[TBL] [Abstract][Full Text] [Related]
5. Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment.
Kroboth PD; Folan MM; Lush RM; Chaikin PC; Shukla UA; Barbhaiya R; Salazar DE
J Clin Psychopharmacol; 1995 Oct; 15(5):306-19. PubMed ID: 8830061
[TBL] [Abstract][Full Text] [Related]
6. Comparison of acute alprazolam (0.25, 0.50 and 1.0 mg) effects versus those of lorazepam 2 mg and placebo on memory in healthy volunteers using laboratory and telephone tests.
Vermeeren A; Jackson JL; Muntjewerff ND; Quint PJ; Harrison EM; O'Hanlon JF
Psychopharmacology (Berl); 1995 Mar; 118(1):1-9. PubMed ID: 7597114
[TBL] [Abstract][Full Text] [Related]
7. A method for determining the magnitude of change across different cognitive functions in clinical trials: the effects of acute administration of two different doses alprazolam.
Snyder PJ; Werth J; Giordani B; Caveney AF; Feltner D; Maruff P
Hum Psychopharmacol; 2005 Jun; 20(4):263-73. PubMed ID: 15912482
[TBL] [Abstract][Full Text] [Related]
8. Different acute tolerance development to EEG, psychomotor performance and subjective assessment effects after two intermittent oral doses of alprazolam in healthy volunteers.
Barbanoj MJ; Urbano G; Antonijoan R; Ballester MR; Valle M
Neuropsychobiology; 2007; 55(3-4):203-12. PubMed ID: 17878744
[TBL] [Abstract][Full Text] [Related]
9. Effects of alprazolam on driving ability, memory functioning and psychomotor performance: a randomized, placebo-controlled study.
Verster JC; Volkerts ER; Verbaten MN
Neuropsychopharmacology; 2002 Aug; 27(2):260-9. PubMed ID: 12093599
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of the psychomotor and antistress effects of ritanserin, alprazolam and diazepam in healthy subjects: some trait anxiety-independent responses.
Danjou P; Warot D; Hergueta T; Lacomblez L; Bouhours P; Puech AJ
Int Clin Psychopharmacol; 1992 Nov; 7(2):73-9. PubMed ID: 1487624
[TBL] [Abstract][Full Text] [Related]
11. Dose-response evaluation of the interaction between sertraline and alprazolam in vivo.
Hassan PC; Sproule BA; Naranjo CA; Herrmann N
J Clin Psychopharmacol; 2000 Apr; 20(2):150-8. PubMed ID: 10770452
[TBL] [Abstract][Full Text] [Related]
12. Anxiolytics and memory: a comparison of lorazepam and alprazolam.
Kumar R; Mac DS; Gabrielli WF; Goodwin DW
J Clin Psychiatry; 1987 Apr; 48(4):158-60. PubMed ID: 3558328
[TBL] [Abstract][Full Text] [Related]
13. [The cognitive effect of alprazolam in healthy volunteers].
Drabant S; Tömlo J; Tóth M; Péterfai E; Klebovich I
Acta Pharm Hung; 2006; 76(1):25-31. PubMed ID: 17094673
[TBL] [Abstract][Full Text] [Related]
14. Absence of neuropsychologic deficits in patients receiving long-term treatment with alprazolam-XR for panic disorder.
Gladsjo JA; Rapaport MH; McKinney R; Auerbach M; Hahn T; Rabin A; Oliver T; Haze A; Judd LL
J Clin Psychopharmacol; 2001 Apr; 21(2):131-8. PubMed ID: 11270908
[TBL] [Abstract][Full Text] [Related]
15. The acute and chronic performance effects of alprazolam and lorazepam in the elderly: relationship to duration of treatment and self-rated sedation.
Pomara N; Tun H; DaSilva D; Hernando R; Deptula D; Greenblatt DJ
Psychopharmacol Bull; 1998; 34(2):139-53. PubMed ID: 9640992
[TBL] [Abstract][Full Text] [Related]
16. Alprazolam 0.125 mg twice a day improves aspects of psychometric performance in healthy volunteers.
Bourin M; Colombel MC; Guitton B
J Clin Psychopharmacol; 1998 Oct; 18(5):364-72. PubMed ID: 9790153
[TBL] [Abstract][Full Text] [Related]
17. A process-based approach to characterizing the effect of acute alprazolam challenge on visual paired associate learning and memory in healthy older adults.
Pietrzak RH; Scott JC; Harel BT; Lim YY; Snyder PJ; Maruff P
Hum Psychopharmacol; 2012 Nov; 27(6):549-58. PubMed ID: 23027677
[TBL] [Abstract][Full Text] [Related]
18. Do the Cambridge Neuropsychological Test Automated Battery episodic memory measures discriminate amnestic mild cognitive impairment?
Juncos-Rabadán O; Pereiro AX; Facal D; Reboredo A; Lojo-Seoane C
Int J Geriatr Psychiatry; 2014 Jun; 29(6):602-9. PubMed ID: 24150876
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans.
Busto U; Kaplan HL; Zawertailo L; Sellers EM
Clin Pharmacol Ther; 1994 Apr; 55(4):451-63. PubMed ID: 8162672
[TBL] [Abstract][Full Text] [Related]
20. Alprazolam absorption kinetics affects abuse liability.
Mumford GK; Evans SM; Fleishaker JC; Griffiths RR
Clin Pharmacol Ther; 1995 Mar; 57(3):356-65. PubMed ID: 7697954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
